Glatiramer acetate treatment negatively regulates type I interferon signaling
Citation Manager Formats
Make Comment
See Comments
See original article:

In the article “Glatiramer acetate treatment negatively regulates type I interferon signaling” by N. Molnarfi et al. (Neurol Neuroimmunol Neuroinflamm 2015;2:e179. DOI: 10.1212/NXI.0000000000000179), originally published on November 9, 2015, there is an error in the description of figure 2B. This figure shows IκBα degradation, not IκBα phosphorylation as originally described. In Methods (“Western blot”), the second sentence should read “Nitrocellulose membranes were probed (4°C, overnight) with antibodies against phospho-Akt1 (Ser473), phospho-JNK (Thr183/Tyr185), phospho-p38 MAP kinase (Thr180/Tyr182), IĸBɑ, glyceraldehyde-3-phosphate dehydrogenase (GAPDH), total STAT1, and total Akt1/2/3 (Cell Signaling Technology, Danvers, MA).” In figure 2, the label above panel B should read just “IĸBɑ” and the corresponding sentence in the legend should read “…and membranes were probed for IĸBɑ.” In the second paragraph under Results (“GA inhibits TRIF-dependent, but not MyD88-dependent, signaling”), the 13th sentence should read “As shown in figure 2B, GA exposure did not impair degradation of the inhibitor protein IĸBɑ following LPS treatment.” The authors regret this error.
- © 2015 American Academy of Neurology
Letters: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Jeffrey Allen and Dr. Nicholas Purcell
► Watch
Alert Me
Recommended articles
-
Article
Glatiramer acetate treatment negatively regulates type I interferon signalingNicolas Molnarfi, Thomas Prod'homme, Ulf Schulze-Topphoff et al.Neurology - Neuroimmunology Neuroinflammation, November 09, 2015 -
Articles
Multiple sclerosis pharmacogenomicsMaximizing efficacy of therapyDerek J. Pappas, Jorge R. Oksenberg et al.Neurology, December 28, 2009 -
Article
Anti-LINGO-1 has no detectable immunomodulatory effects in preclinical and phase 1 studiesAnn Ranger, Soma Ray, Suzanne Szak et al.Neurology: Neuroimmunology & Neuroinflammation, December 15, 2017 -
Article
B-Cell Compartmental Features and Molecular Basis for Therapy in Autoimmune DiseaseChao Zhang, Tian-Xiang Zhang, Ye Liu et al.Neurology: Neuroimmunology & Neuroinflammation, August 31, 2021